Table 3. Association Between Hospitalization and Patient Characteristics.
Characteristic | Patients | OR (95% CI) | ||||
---|---|---|---|---|---|---|
Total No. (N = 816) | Hospitalized, No. (%) (n = 364) | Not hospitalized, No. (%) (n = 452) | Unadjusted | Multivariablea | ||
Year of reported treatment | ||||||
2011-2016 | 386 | 185 (50.8) | 201 (44.5) | 1.30 (0.98-1.72) | 1.80 (0.86-3.72) | |
2017-2019 | 430 | 179 (49.2) | 251 (55.5) | |||
IV magnesium therapy | ||||||
Total | 215 | 190 (52.2) | 25 (5.5) | 25.87 (15.99-41.84) | 9.76 (4.58-20.77) | |
2011-2016 | NA | NA | NA | NA | 22.67 (6.26-82.06)b | |
2017-2019 | NA | NA | NA | NA | 4.19 (1.99-8.86)b | |
IV magnesium × year interaction | NA | NA | NA | NA | 5.40 (1.25-23.33) | |
Initial PRAM score, mean (SD)c | 816 | 6.6 (1.4) | 5.9 (1.0) | 1.64 (1.45-1.86) | 1.21 (0.99-1.46)d | |
ED disposition PRAM score, mean (SD) | 785 | 4.9 (1.8) | 2.5 (1.3) | 2.70 (2.35-3.11) | 2.24 (1.89-2.65)e | |
Age ≤5 y | 503 | 232 (63.7) | 271 (60.0) | 1.20 (0.89-1.59) | 1.39 (0.86-2.24) | |
Sex | ||||||
Male | 517 | 224 (61.5) | 293 (64.8) | 1.14 (0.86-1.52) | 0.92 (0.57-1.47) | |
Female | 299 | 140 (38.5) | 159 (35.2) | |||
Duration of symptoms ≤12 h before arrival | 321 | 147 (40.4) | 174 (38.5) | 1.12 (0.85-1.51) | 1.56 (0.73-1.84) | |
Past ICU admission for asthma | 79 | 46 (12.1) | 33 (7.7) | 1.74 (1.10-2.80) | 1.66 (0.76-3.66) | |
Hospitalization for asthma in past year | 197 | 103 (28.3) | 94 (20.8) | 1.58 (1.14-2.20) | 0.89 (0.52-1.52) | |
Atopy | 493 | 214 (58.8) | 279 (61.7) | 0.82 (0.62-1.10) | 0.79 (0.49-1.28) | |
Family history of atopy | 603 | 272 (74.7) | 331 (73.2) | 1.10 (0.76-1.47) | 1.06 (0.62-1.81) | |
Oral corticosteroid therapy before arrival | 145 | 74 (20.3) | 71 (15.7) | 1.36 (0.93-1.98) | 1.12 (0.60-2.08) | |
Nebulized magnesium therapy | 409 | 172 (47.3) | 237 (52.4) | 0.81 (0.61-1.07) | 0.97 (0.62-1.51) | |
≥1 Albuterol treatment after experimental therapy | 510 | 318 (87.4) | 192 (42.5) | 11.82 (8.00-17.47) | 5.94 (3.52-10.01) |
Abbreviations: ED, emergency department; ICU, intensive care unit; IV, intravenous; NA, not applicable; OR, odds ratio; PRAM, Pediatric Respiratory Assessment Measure.
The multivariable regression analysis was adjusted for all variables shown.
Adjusted OR for the association between IV magnesium therapy and hospitalization.
Details of the PRAM score are given in Table 1. PRAM score measured after initial therapy with corticosteroids, salbutamol, and ipratropium bromide.
Per 1-U increase in initial PRAM score.
Per 1-U increase in ED disposition PRAM score.